Moderna to Present 2026 Data on Revaccination with mRNA-Based Influenza and RSV Combination Vaccine at ECCMID

Moderna has announced plans to present new data on its investigational seasonal influenza vaccine and mRESVIA, a combination vaccine targeting respiratory syncytial virus (RSV) and influenza. The company will share findings related to revaccination at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in 2026. This presentation will focus on the latest clinical trial results, offering insights into the safety, efficacy, and immune response associated with repeated doses of these vaccines.

The investigational seasonal influenza vaccine is part of Moderna’s broader effort to expand its portfolio of mRNA-based vaccines. Meanwhile, mRESVIA represents an innovative approach by combining protection against two significant respiratory illnesses in a single dose. The data being presented will include information on how individuals respond to multiple doses over time, addressing questions about long-term immunity and potential side effects. These findings are expected to contribute to ongoing discussions about the role of mRNA technology in combating infectious diseases globally.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 6, 2026

Author

GOAI